Key statistics
On Monday, Ocugen Inc (2H51:DUS) closed at 0.90, 177.78% above the 52 week low of 0.324 set on Oct 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.9215 |
---|---|
High | 0.9215 |
Low | 0.8975 |
Bid | -- |
Offer | -- |
Previous close | 0.908 |
Average volume | 7.07k |
---|---|
Shares outstanding | 287.86m |
Free float | 283.79m |
P/E (TTM) | -- |
Market cap | 290.74m USD |
EPS (TTM) | -0.1785 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 18:30 BST.
More ▼
Announcements
- Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
- Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
- Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
- Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
- Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
- Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
- Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
- Ocugen Provides Business Update with Second Quarter 2024 Financial Results
- Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
- Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
More ▼